ILMN Stock Quote
Company Report
Illumina, Inc. specializes in providing advanced sequencing and array-based solutions that revolutionize genetic and genomic analysis across diverse sectors. Founded in 1998 and headquartered in San Diego, California, the company serves a broad spectrum of markets, facilitating the integration of genomic technologies in research and clinical applications spanning life sciences, oncology, reproductive health, agriculture, and emerging fields.
The core offerings of Illumina encompass instruments and consumables essential for genetic analysis, including genotyping and sequencing services, instrument service contracts, and collaborative development and licensing agreements. Notably, the company also offers cancer detection testing services, leveraging its cutting-edge technologies to advance diagnostics and personalized medicine.
Illumina caters to a diverse clientele that includes genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology firms, commercial molecular diagnostic labs, and consumer genomics enterprises. With a strategic global presence, the company markets and distributes its products directly across North America, Europe, Latin America, and the Asia-Pacific region, bolstered by partnerships with life-science distributors in key international markets such as Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Illumina continues to drive innovation in genomics, contributing significantly to advancements in healthcare and biological research worldwide.
ILMN EPS Chart
ILMN Revenue Chart